ELUT · NASDAQ
Elutia Inc
$0.79 +0.03 (+3.76%)
Company overview
Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection, Women's Health, and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure, Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients, and VasCure, a patch material to repair or reconstruct the peripheral vasculature.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $35M
- Employees
- 26
- Headquarters
- Gaithersburg, MD
- Website
- elutia.com
- CEO
- C. Randal Mills
- Listed
- October 7, 2020
- P/E
- 0.63
- Dividend yield
- 0.00%
Company financials
- Revenue
- $16M
- Gross profit
- $8.6M
- Operating income
- -$25.5M
- EBITDA
- -$18.2M
- Net income
- $49.8M
- EPS
- $1.25
- Total assets
- $55.2M
- Total debt
- $6.1M
- Gross margin
- 54.02%
- Net margin
- 312.09%
- Earnings yield
- 158.35%
No geographic segmentation.
Showing FY 2025
ELUT
1D
NASDAQ
O0.82H0.82L0.75C0.76-0.05 (-6.59%)Vol93.54K
News